LIDDS AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 2
- Market Cap
- -
- Website
- http://www.liddspharma.com
Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- Lidds AB
- Target Recruit Count
- 6
- Registration Number
- NCT04810208
- Locations
- 🇱🇹
National Cancer Institute, Vilnius, Lithuania
🇩🇰Herlev Hospital, Copenhagen, Denmark
🇸🇪Karolinska University Hospital, Stockholm, Sweden
A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Lidds AB
- Target Recruit Count
- 61
- Registration Number
- NCT03348527
- Locations
- 🇫🇮
Tampere University Hospital, Tampere, Finland
🇨🇦Jonathan Giddens Medicine Professional Corporation, Brampton, Ontario, Canada
🇨🇦Nova Scotia Health Authority, Halifax, Nova Scotia, Canada
A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Lidds AB
- Target Recruit Count
- 23
- Registration Number
- NCT02341404
- Locations
- 🇸🇪
Dept of Urology, University Hospital, Uppsala, Sweden
An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2015-01-19
- Lead Sponsor
- Lidds AB
- Target Recruit Count
- 24
- Registration Number
- NCT00913263
- Locations
- 🇫🇮
Tampere University Hospital, Tampere, Finland
© Copyright 2024. All Rights Reserved by MedPath